Optimizing Treatment in Patients with ROS1 Rearranged NSCLC
Annenberg Center for Health Sciences
1 episodes
4 days ago
Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications.
All content for Optimizing Treatment in Patients with ROS1 Rearranged NSCLC is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications.
Optimizing Treatment in Patients with ROS1 Rearranged NSCLC
Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications.
